未知生产厂商
Daxdilimab is under investigation in clinical trial NCT04526912 (Treatment and Prevention of Acute Lung Injury (ALI) in Patients With COVID-19 Infection).
Daxdilimab is under investigation in clinical trial NCT04526912 (Treatment and Prevention of Acute Lung Injury (ALI) in Patients With COVID-19 Infection).
Daxdilimab is a novel drug designed to target and bind to ILT7, which is a cell surface molecule specific to the pDC type of dendritic cells. It is currently being investigated against autoimmune diseases and COVID-19.
